HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1

Published:2019-03-18 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Jing Chu-Yu,Fu Yi-Peng,Yi Yong,Zhang Mei-Xia,Zheng Su-Su,Huang Jin-Long,Gan Wei,Xu Xin,Lin Jia-Jia,Zhang Juan,Qiu Shuang-Jian,Zhang Bo-Heng

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0554-8.pdf

Reference34 articles.

1. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.

2. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.

3. Li J, Wang Q, Lei Z, Wu D, Si A, Wang K, et al. Adjuvant Transarterial chemoembolization following liver resection for intrahepatic cholangiocarcinoma based on survival risk stratification. Oncologist. 2015;20(6):640–7.

4. Capecitabine Extends Survival for Biliary Tract Cancer. Cancer Discov. 2017;7(7):OF1.

5. Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13(3):143–58.

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of HHLA2: identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinoma;Cancer Immunology, Immunotherapy;2024-08-06

2. Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma;Biomedicine & Pharmacotherapy;2024-08

3. Small duct and large duct type intrahepatic cholangiocarcinoma reveal distinct patterns of immune signatures;Journal of Cancer Research and Clinical Oncology;2024-07-22

4. Enhancing hepatocellular carcinoma management: prognostic value of integrated CCL17, CCR4, CD73, and HHLA2 expression analysis;Journal of Cancer Research and Clinical Oncology;2024-06-25

5. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma;Biomedicine & Pharmacotherapy;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3